Risk of symptomatic intracerebral hemorrhage in patients treated with intra-arterial thrombolysis for the MR stroke study group investigators

Cerebrovascular Diseases

Volumn 27, Issue 4, 2009, Pages 368-374

  Singer, O C ^a   Berkefeld, J ^a   Lorenz, M W ^a   Fiehler, J ^b   Albers, G W ^c   Lansberg, M G ^c   Kastrup, A ^d,e   Rovira, A ^f   Liebeskind, D S ^g   Gass, A ^h   Rosso, C ⁱ   Derex, L ^j   Kim, J S ^k   Neumann Haefelin, T ^a  

^a GOETHE UNIVERSITY   (Germany)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^c STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^d Neurologische Klinik   (Germany)

^e UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^f HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h UNIVERSITY OF HEIDELBERG   (Germany)

ⁱ ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^j UNIVERSITÉ DE LYON   (France)

^k University of Ulsan   (South Korea)

more..

Author keywords

Hemorrhage, intracerebral; Stroke, acute; Thrombolysis, Intra arterial

Indexed keywords

ALTEPLASE; UROKINASE;

ADULT; AGED; ARTICLE; BLOOD CLOT LYSIS; BRAIN HEMORRHAGE; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RISK ASSESSMENT; STROKE;

AGED; CEREBRAL HEMORRHAGE; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; INJECTIONS, INTRA-ARTERIAL; INJECTIONS, INTRAVENOUS; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; RETROSPECTIVE STUDIES; RISK FACTORS; STROKE; THROMBOLYTIC THERAPY; TISSUE PLASMINOGEN ACTIVATOR; UROKINASE-TYPE PLASMINOGEN ACTIVATOR;

EID: 59849092089     PISSN: 10159770     EISSN: None     Source Type: Journal    
DOI: 10.1159/000202427     Document Type: Article

References (25)

1. The NINDS study group: Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995; 333: 1581-1587.
2. Labiche LA, Al-Senani F, Wojner AW, Grotta JC, Malkoff M, Alexandrov AV: Is the benefit of early recanalization sustained at 3 months? A prospective cohort study. Stroke 2003; 34: 695-698.
3. Alexandrov AV, Grotta JC: Arterial reocclusion in stroke patients treated with intravenous tissue plasminogen activator. Neurology 2002; 59: 862-867.
4. Furlan A, Higashida R, Wechsler L, Gent M, Rowley H, Kase C, Pessin M, Ahuja A, Callahan F, Clark WM, Silver F, Rivera F: Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: a randomized controlled trial. Prolyse in acute cerebral thromboembolism. JAMA 1999; 282: 2003-2011.
5. Combined intravenous and intra-arterial recanalization for acute ischemic stroke: the Interventional Management of Stroke Study. Stroke 2004; 35: 904-911.
6. Lewandowski CA, Frankel M, Tomsick TA, Broderick J, Frey J, Clark W, Starkman S, Grotta J, Spilker J, Khoury J, Brott T: Combined intravenous and intra-arterial r-tPA versus intra-arterial therapy of acute ischemic stroke: emergency management of stroke (EMS) bridging trial. Stroke 1999; 30: 2598-2605.
7. Mattle HP, Arnold M, Georgiadis D, Baumann C, Nedeltchev K, Benninger D, Remonda L, von Budingen C, Diana A, Pan galu A, Schroth G, Baumgartner RW: Comparison of intraarterial and intravenous thrombolysis for ischemic stroke with hyperdense middle cerebral artery sign. Stroke 2008; 39: 379-383.
8. Hacke W, Donnan G, Fieschi C, Kaste M, von Kummer R, Broderick JP, Brott T, Frankel M, Grotta JC, Haley EC Jr, Kwiatkowski T, Levine SR, Lewandowski C, Lu M, Lyden P, Marler JR, Patel S, Tilley BC, Albers G, Bluhmki E, Wilhelm M, Hamilton S: Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet 2004; 363: 768-774.
9. The Interventional Management of Stroke (IMS) II Study. Stroke 2007; 38: 2127-2135.
10. Kidwell CS, Saver JL, Carneado J, Sayre J, Starkman S, Duckwiler G, Gobin YP, Jahan R, Vespa P, Villablanca JP, Liebeskind DS, Vinuela F: Predictors of hemorrhagic transformation in patients receiving intra-arterial thrombolysis. Stroke 2002; 33: 717-724.
11. 2* -weighted magnetic resonance imaging data from 570 patients. Stroke 2007;38: 2738-2744.
12. Neumann-Haefelin T, Hoelig S, Berkefeld J, Fiehler J, Gass A, Humpich M, Kastrup A, Kucinski T, Lecei O, Liebeskind DS, Rother J, Rosso C, Samson Y, Saver JL, Yan B: Leukoaraiosis is a risk factor for symptomatic intracerebral hemorrhage after thrombolysis for acute stroke. Stroke 2006; 37: 2463-2466.
13. Singer OC, Humpich MC, Fiehler J, Albers GW, Lansberg MG, Kastrup A, Rovira A, Liebeskind DS, Gass A, Rosso C, Derex L, Kim JS, Neumann-Haefelin T: Risk for symptomatic intracerebral hemorrhage after thrombolysis assessed by diffusion-weighted magnetic resonance imaging. Ann Neurol 2008; 63: 52-60.
14. Larrue V, von Kummer R, del Zoppo G, Bluhmki E: Hemorrhagic transformation in acute ischemic stroke. Potential contributing factors in the European cooperative acute stroke study. Stroke 1997; 28: 957-960.
15. Kothari RU, Brott T, Broderick JP, Barsan WG, Sauerbeck LR, Zuccarello M, Khoury J: The ABCs of measuring intracerebral hemorrhage volumes. Stroke 1996; 27: 1304-1305.
16. Marcus R, Peritz E, Gabriel KG: On closed testing procedures with special reference to ordered analysis of variance. Biometrika 1976; 63: 656-660.
17. Lansberg MG, Thijs VN, Bammer R, Kemp S, Wijman CA, Marks MP, Albers GW: Risk factors of symptomatic intracerebral hemorrhage after t-PA therapy for acute stroke. Stroke 2007; 38: 2275-2278.
18. Hacke W, Kaste M, Fieschi C, von Kummer R, Davalos A, Meier D, Larrue V, Bluhmki E, Davis S, Donnan G, Schneider D, Diez-Tejedor E, Trouillas P: Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian acute stroke study investigators. Lancet 1998; 352: 1245-1251.
19. Wahlgren N, Ahmed N, Davalos A, Ford GA, Grond M, Hacke W, Hennerici MG, Kaste M, Kuelkens S, Larrue V, Lees KR, Roine RO, Soinne L, Toni D, Vanhooren G: Thrombolysis with alteplase for acute ischaemic stroke in the safe implementation of thrombolysis in stroke-monitoring study (SITS-MOST): an observational study. Lancet 2007; 369: 275-282.
20. Shaltoni HM, Albright KC, Gonzales NR, Weir RU, Khaja AM, Sugg RM, Campbell MS 3rd, Cacayorin ED, Grotta JC, Noser EA: Is intra-arterial thrombolysis safe after fulldose intravenous recombinant tissue plasminogen activator for acute ischemic stroke? Stroke 2006; 38: 80-84.
21. Flaherty ML, Woo D, Kissela B, Jauch E, Pancioli A, Carrozzella J, Spilker J, Sekar P, Broderick J, Tomsick T: Combined IV and intra-arterial thrombolysis for acute ischemic stroke. Neurology 2005; 64: 386-388.
22. Brekenfeld C, Remonda L, Nedeltchev K, Arnold M, Mattle HP, Fischer U, Kappeler L, Schroth G: Symptomatic intracranial haemorrhage after intra-arterial thrombolysis in acute ischaemic stroke: assessment of 294 patients treated with urokinase. J Neurol Neurosurg Psychiatry 2007; 78: 280-285.
23. Tanne D, Kasner SE, Demchuk AM, Koren-Morag N, Hanson S, Grond M, Levine SR: Markers of increased risk of intracerebral hemorrhage after intravenous recombinant tissue plasminogen activator therapy for acute ischemic stroke in clinical practice: the multicenter rt-PA stroke survey. Circulation 2002; 105: 1679-1685.
24. Albers GW, Thijs VN, Wechsler L, et al: Magnetic resonance imaging profiles predict clinical response to early reperfusion: the diffusion and perfusion imaging evaluation for understanding stroke evolution (DEFUSE) study. Ann Neurol 2006;60:508-517.
25. del Zoppo GJ, Higashida RT, Fulan AJ, et al: PROACT: a phase II randomized trial of recombinant pro-urokinase by direct arterial delivery in acute middle cerebral artery stroke. PROACT Investigators. Prolyse in Acute Cerebral Thromboembolism. Stroke 1998;29:4-11.